Impact of IL-27 on Regulatory T Cell Responses
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon -
A1068-CD86 Polyclonal Antibody
BioVision 05/16 For research use only CD86 Polyclonal Antibody CATALOG NO: A1068-100 ALTERNATIVE NAMES: T-lymphocyte activation antigen CD86, Activation B7-2 antigen, B70, BU63, CTLA-4 counter-receptor B72, FUN-1, CD86, CD86, CD28LG2 Western blot analysis of CD86 in NCI-H292 cell line lysate AMOUNT: 100 µl IMMUNOGEN: KLH conjugated synthetic peptide between 269-298 amino acids from the C-terminal region of human CD86. MOLECULAR WEIGHT: 37 kDa HOST/ISOTYPE: Rabbit IgG SPECIES REACTIVITY: Human PURIFICATION: This antibody is purified through a protein A column, followed by peptide affinity purification. FORM: Liquid FORMULATION: Supplied in PBS with 0.09% (W/V) sodium azide. STORAGE CONDITIONS: Maintain refrigerated at 2-8°C for up to 6 months. For long term RELATED PRODUCTS storage store at -20°C in small aliquots to prevent freeze-thaw cycles. DESCRIPTION: This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by Human CellExp™ B7-2 /CD86, human recombinant (Cat. No. 7496-10, -50) antigen-presenting cells, and it is the ligand for two proteins at the CD86 (Human) ELISA Kit (Cat. No. K4175-100) cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte- Human CellExp™LAG3 /CD223, human recombinant (Cat. No. 7278-10, -50) associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this CD223 (LAG3) Polyclonal Antibody (Cat. No. A1067-100) protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. -
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples Qiang Liu Chinese Academy of Medical Sciences & Peking Union Medical College Yihang Qi ( [email protected] ) Chinese Academy of Medical Sciences and Peking Union Medical College https://orcid.org/0000-0001- 7589-0333 Jie Zhai Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyi Kong Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyu Wang Chinese Academy of Medical Sciences & Peking Union Medical College Yi Fang Chinese Academy of Medical Sciences & Peking Union Medical College Jing Wang Chinese Academy of Medical Sciences & Peking Union Medical College Research Keywords: Cancer immunotherapy, CD223, LAG3, Immune response, Inammatory activity Posted Date: June 19th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-36422/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/33 Abstract Background Despite the promising impact of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a large number of cancer patients fail to respond. LAG3 (Lymphocyte Activating 3), also named CD233, is a protein Coding gene served as alternative inhibitory receptors to be targeted in the clinic. The impact of LAG3 on immune cell populations and co-regulation of immune response in breast cancer remained largely unknown. Methods To characterize the role of LAG3 in breast cancer, we investigated transcriptome data and associated clinical information derived from a total of 2994 breast cancer patients. Results We observed that LAG3 was closely correlated with major molecular and clinical characteristics, and was more likely to be enriched in higher malignant subtype, suggesting LAG3 was a potential biomarker of triple-negative breast cancer. -
Diabetes in the Absence of LAG-3 Cutting Edge
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3 Maria Bettini, Andrea L. Szymczak-Workman, Karen Forbes, Ashley H. Castellaw, Mark Selby, Xiaoyu Pan, This information is current as Charles G. Drake, Alan J. Korman and Dario A. A. Vignali of September 24, 2021. J Immunol 2011; 187:3493-3498; Prepublished online 26 August 2011; doi: 10.4049/jimmunol.1100714 http://www.jimmunol.org/content/187/7/3493 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2011/08/26/jimmunol.110071 Material 4.DC1 http://www.jimmunol.org/ References This article cites 25 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/187/7/3493.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3 Maria Bettini,* Andrea L. -
Point Mutation in CD19 Facilitates Immune Escape of B Cell Lymphoma from CAR-T Cell Therapy
Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-001150 on 6 October 2020. Downloaded from Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR- T cell therapy 1 1 1 1 1 1 Zhen Zhang, Xinfeng Chen, Yonggui Tian, Feng Li , Xuan Zhao, Jinyan Liu, 1 1,2,3,4 Chang Yao, Yi Zhang To cite: Zhang Z, Chen X, ABSTRACT relapses after CD19 CAR-T cell therapy are Tian Y, et al. Point mutation Background Tumor relapse due to mutation in CD19 can attributed to the antigen loss, indicating an in CD19 facilitates immune hinder the efficacy of chimeric antigen receptor (CAR)- T urgent need for investigating the mechanisms escape of B cell lymphoma from cell therapy. Herein, we focused on lymphoma patients CAR- T cell therapy. Journal underlying recurrence and for improving whose B cells exhibited a point mutation in CD19 of B cells 4 5 for ImmunoTherapy of Cancer the efficacy of CAR- T cell therapy. Inter- 2020; :e001150. doi:10.1136/ after CAR-T cell infusion. 8 + estingly, one of the specific mechanisms jitc-2020-001150 Methods The CAR- T and CD19 B cells from peripheral blood or bone marrow were assessed using flow of tumor escape that has been reported cytometry. Genome sequencing was conducted to identify suggests that exon mutations affecting the ► Additional material is + published online only. To view, the molecular characteristics of CAR- T and CD19 B cells CD19 gene and its splicing isoforms, leading please visit the journal online from pre-rela pse and postrelapse samples. -
LAG-3: from Molecular Functions to Clinical Applications
Open access Review J Immunother Cancer: first published as 10.1136/jitc-2020-001014 on 13 September 2020. Downloaded from LAG-3: from molecular functions to clinical applications Takumi Maruhashi , Daisuke Sugiura , Il- mi Okazaki , Taku Okazaki To cite: Maruhashi T, Sugiura D, ABSTRACT (PD-1) and cytotoxic T lymphocyte antigen Okazaki I, et al. LAG-3: from To prevent the destruction of tissues owing to excessive 4 (CTLA-4) significantly improved the molecular functions to clinical and/or inappropriate immune responses, immune outcomes of patients with diverse cancer applications. Journal for cells are under strict check by various regulatory ImmunoTherapy of Cancer types, revolutionizing cancer treatment. The mechanisms at multiple points. Inhibitory coreceptors, 2020;8:e001014. doi:10.1136/ success of these therapies verified that inhib- including programmed cell death 1 (PD-1) and cytotoxic jitc-2020-001014 itory coreceptors serve as critical checkpoints T lymphocyte antigen 4 (CTLA-4), serve as critical checkpoints in restricting immune responses against for immune cells to not attack the tumor Accepted 29 July 2020 self- tissues and tumor cells. Immune checkpoint inhibitors cells as well as self-tissues. However, response that block PD-1 and CTLA-4 pathways significantly rates are typically lower and immune-related improved the outcomes of patients with diverse cancer adverse events (irAEs) are also observed in types and have revolutionized cancer treatment. However, patients administered with immune check- response rates to such therapies are rather limited, and point inhibitors. This is indicative of the immune-rela ted adverse events are also observed in a continued need to decipher the complex substantial patient population, leading to the urgent need biology of inhibitory coreceptors to increase for novel therapeutics with higher efficacy and lower response rates and prevent such unwanted toxicity. -
A Folding Switch Regulates Interleukin 27 Biogenesis and Secretion of Its Α-Subunit As a Cytokine
A folding switch regulates interleukin 27 biogenesis and secretion of its α-subunit as a cytokine Stephanie I. Müllera,b, Antonie Friedlc, Isabel Aschenbrennera,b, Julia Esser-von Bierenc, Martin Zachariasd, Odile Devergnee,1, and Matthias J. Feigea,b,1 aCenter for Integrated Protein Science, Department of Chemistry, Technical University of Munich, 85748 Garching, Germany; bInstitute for Advanced Study, Technical University of Munich, 85748 Garching, Germany; cCenter of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, 80802 Munich, Germany; dCenter for Integrated Protein Science, Physics Department, Technical University of Munich, 85748 Garching, Germany; and eSorbonne Université, INSERM, CNRS, Centre d’Immunologie et des Maladies Infectieuses, 75 013 Paris, France Edited by John J. O’Shea, NIH, Bethesda, MD, and accepted by Editorial Board Member Tadatsugu Taniguchi December 10, 2018 (received for review October 3, 2018) A common design principle of heteromeric signaling proteins is the by the secretion and biological activity of some isolated α-and use of shared subunits. This allows encoding of complex messages β-subunits (10, 11). A prominent example is IL-27α/p28. Murine IL- while maintaining evolutionary flexibility. How cells regulate and 27α, also designated as IL-30, is secreted in isolation (12) and per- control assembly of such composite signaling proteins remains an forms immunoregulatory roles (13–16). In contrast, no autonomous important open question. An example of particular complexity and secretion of human IL-27α has been reported yet. The molecular biological relevance is the interleukin 12 (IL-12) family. Four func- basis for this difference has remained unclear, but it is likely to have tionally distinct αβ heterodimers are assembled from only five sub- a profound impact on immune system function, since in mice IL-27 units to regulate immune cell function and development. -
Lymphocyte Activation Gene-3 – the Expression and Function in the Immune System
Lymphocyte Activation Gene-3 – the expression and function in the immune system Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-naturwissenschaftlichen Fakultät der Universität Basel von Malgorzata Kisielow aus Edmonton, Kanada Basel, 2006 Genehmigt von der Philosphisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Antonius Rolink und PD. Dr. Patrick Matthias Basel, den 24 Mai 2005 Prof. Dr. Hans-Jakob Wirz 2 Mojej Mamie Mojemu Tacie 3 TABLE OF CONTENTS ABBREVIATIONS 7 SUMMARY 9 1. INTRODUCTION 11 1.1. The immune system 11 1.1.1. Players of adaptive immunity 12 1.1.1.1. B lymphocytes 12 - B2 B cells 13 - B1 B cells 13 - Marginal zone B cells 14 1.1.1.2. T lymphocytes 14 - αβ T cells 15 Helper T cells 15 Cytotoxic T cells 16 Regulatory T cells 16 NK T cells 17 - γδ T cells 18 1.1.1.3. Antigen Presenting Cells 18 - Denritic cells 19 1.1.1.4. Natural Killer Cells 21 1.1.2. Lymphocyte homeostasis 21 1.1.3. T cell responses 22 1.1.4. T cell-B cell collaboration in B cell responses 24 - Germinal Center reaction 27 1.2. Lymphocyte Activation Gene-3 28 1.2.1. Identification and the predicted structure 28 1.2.2. LAG-3 expression pattern 31 1.2.3. Regulation of Lag-3 expression 33 1.2.4. Suggested function of LAG-3 35 1.2.5. Mode of action of LAG-3 36 1.2.6. LAG-3 and cancer 38 2. THESIS OBJECTIVES 40 3. -
1 Interleukin 27 Is a Potential Rescue Therapy for Acute Severe Colitis Via Interleukin-10 Dependent, T
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Aberdeen University Research Archive 1 1 Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T 2 cell independent attenuation of colonic mucosal innate immune responses 3 Mairi H McLean1,2, Caroline Andrews1, Miranda L Hanson1, Walter A Baseler1, Miriam R Anver3, 4 Emilee Senkevitch1, Aleksandra K Staniszewska1,2, Christopher Smith1,2, Luke C Davies1, Julie Hixon1, 5 Wenqeng Li1, Wei Shen1, Lothar Steidler4, Scott K Durum1 6 7 1Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, 8 Maryland, 21702, USA; 2School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, 9 Scotland, AB25 2ZD, UK; 3Pathology/Histotechnology Laboratory, Laboratory Animal Sciences 10 Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, 11 Frederick, Maryland, 21702, USA; 4Intrexon Actobiotics N.V., 9052 Zwijnaarde, Belgium 12 Short title; IL-27 attenuates colonic innate immune responses 13 * Correspondence Dr. Scott K Durum 14 National Cancer Institute, Laboratory of Molecular Immunoregulation, Bldg 560, 15 1050 Boyles Street, Frederick, MD 21702-1201 16 Tel: +1-301-846-1545, Fax: +1-301-846-6752 17 Email: [email protected] 18 Conflicts of Interest and Source of Funding 19 Lothar Steidler is a shareholder of Intrexon Corporation and employee of Intrexon Actobiotics N.V. The 20 other authors have declared that no conflict of interest exists. 2 21 This work was supported in part by the Intramural Research Program of the National Institutes of Health, 22 National Cancer Institute, as well as a fellowship funded by Crohn’s and Colitis Foundation of America 23 (MHM) and a grant from the Broad Medical Research Foundation. -
Wsx-1/Il-27 As a Target for Anti-Inflammatory Responses
(19) TZZ ZZ_T (11) EP 2 046 809 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 1/00 (2006.01) C07K 14/54 (2006.01) 07.12.2016 Bulletin 2016/49 C07K 14/715 (2006.01) C07K 16/24 (2006.01) (21) Application number: 07836143.3 (86) International application number: PCT/US2007/016329 (22) Date of filing: 18.07.2007 (87) International publication number: WO 2008/011081 (24.01.2008 Gazette 2008/04) (54) WSX-1/IL-27 AS A TARGET FOR ANTI-INFLAMMATORY RESPONSES WSX-1/IL-27 ALS TARGET FÜR ENTZÜNDUNGSHEMMENDE REAKTIONEN WSX-1/IL-27 UTILISÉ COMME CIBLE POUR SUSCITER DES RÉACTIONS ANTI-INFLAMMATOIRES (84) Designated Contracting States: • VILLARINO ALEJANDRO V ET AL: "IL-27 limits AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IL-2 production during Th1 differentiation." HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE JOURNALOF IMMUNOLOGY (BALTIMORE, MD. : SI SK TR 1950) 1 JAN 2006, vol. 176, no. 1, 1 January 2006 Designated Extension States: (2006-01-01), pages 237-247, XP002570061 ISSN: AL BA RS 0022-1767 • KASTELEIN ROBERT A ET AL: "Discovery and (30) Priority: 19.07.2006 US 832213 P biologyof IL-23 andIL-27: relatedbut functionally 11.08.2006 US 837450 P distinct regulators of inflammation." ANNUAL REVIEW OF IMMUNOLOGY 2007, vol. 25, 2007, (43) Date of publication of application: pages 221-242, XP002570062 ISSN: 0732-0582 15.04.2009 Bulletin 2009/16 • SCHELLER J ET AL: "No inhibition of IL-27 signaling by soluble gp130" BIOCHEMICAL AND (73) Proprietor: The Trustees of The University of BIOPHYSICAL RESEARCH COMMUNICATIONS, Pennsylvania ACADEMIC PRESS INC. -
Novel Insights Into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells
Published OnlineFirst August 31, 2011; DOI: 10.1158/1078-0432.CCR-11-1724 Clinical Cancer Molecular Pathways Research Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells Nicola Giuliani1 and Irma Airoldi2 Abstract Multiple myeloma is a monoclonal postgerminal center tumor that has phenotypic features of plasmablasts and/or plasma cells and usually localizes at multiple sites in the bone marrow. The pathogenesis of multiple myeloma is complex and dependent on the interactions between tumor cells and their microenvironment. Different cytokines, chemokines, and proangiogenic factors released in the tumor microenvironment are known to promote multiple myeloma cell growth. Here, we report recent advances on the role of 2 strictly related immunomodulatory cytokines, interleukin-27 (IL-27) and IL-23, in human normal and neoplastic plasma cells, highlighting their ability to (i) act directly against multiple myeloma cells, (ii) influence the multiple myeloma microenvironment by targeting osteoclast and osteoblast cells, and (iii) modulate normal plasma cell function. Finally, the therapeutic implication of these studies is discussed. Clin Cancer Res; 17(22); 6963–70. Ó2011 AACR. Background resulting in enhancement the of na€ve cluster of differen- þ tiation (CD)4 T-cell proliferation, promotion of the early Interleukin (IL)-27 and IL-23 are immunomodulatory T-helper (Th)1 differentiation, and suppression of the cytokines that belong to the IL-12 superfamily (1), which differentiation of Th2 and Th17 cells. In addition, IL-27 comprises structurally and functionally related heterodi- plays a key role in generating IL-10–producing regulatory meric cytokines, including IL-12, IL-23, IL-27, and IL-35 T cells (1, 9). -
Circulating Exosomes Inhibit B Cell Proliferation and Activity
cancers Article Circulating Exosomes Inhibit B Cell Proliferation and Activity Jan C. Schroeder , Lisa Puntigam, Linda Hofmann , Sandra S. Jeske, Inga J. Beccard, Johannes Doescher, Simon Laban, Thomas K. Hoffmann, Cornelia Brunner , , Marie-Nicole Theodoraki y and Patrick J. Schuler * y Department of Otorhinolaryngology and Head and Neck Surgery, Ulm University, 89075 Ulm, Germany; [email protected] (J.C.S.); [email protected] (L.P.); [email protected] (L.H.); [email protected] (S.S.J.); [email protected] (I.J.B.); [email protected] (J.D.); [email protected] (S.L.); T.hoff[email protected] (T.K.H.); [email protected] (C.B.); [email protected] (M.-N.T.) * Correspondence: [email protected]; Tel.: +49-731-500-59501 These authors contributed equally. y Received: 23 June 2020; Accepted: 24 July 2020; Published: 29 July 2020 Abstract: (1) Background: Head and neck squamous cell carcinoma (HNSCC) is characterized by a distinctive suppression of the anti-tumor immunity, both locally in the tumor microenvironment (TME) and the periphery. Tumor-derived exosomes mediate this immune suppression by directly suppressing T effector function and by inducing differentiation of regulatory T cells. However, little is known about the effects of exosomes on B cells. (2) Methods: Peripheral B cells from healthy donors and HNSCC patients were isolated and checkpoint receptor expression was analyzed by flow cytometry. Circulating exosomes were isolated from the plasma of HNSCC patients (n = 21) and healthy individuals (n = 10) by mini size-exclusion chromatography.